We use cookies to improve user experience, and analyze website traffic.
For these reasons, we may share your site usage data with our analytics partners. By clicking "Accept Cookies" you consent to store on your device all the technologies described in our Cookie Policy.
In a regulatory filing, Privia Health Group director Jeffrey Daniel Bernstein disclosed the sale of 24,819,473 common shares of the company on May 8 at a price of $21.615 per share.
Canaccord lowered the firm's price target on Privia Health to $44 from $45 and keeps a Buy rating on the shares. The analyst said Privia reported a solid quarter that beat estimates across the board and reaffirmed annual guidance at this early stage in the year.
SVB Securities analyst Whit Mayo raised the firm's price target on Privia Health to $40 from $39 and keeps an Outperform rating on the shares following the "strong" Q1 results. The analyst says ambulatory end-market demand remains strong.
Privia Health Group announced the upsized pricing of an underwritten secondary offering of 42,561,196 shares of common stock by certain selling stockholders at a price of $22.00 per share. The Company will not receive any of the proceeds from the sale of the shares of its common stock, and the selling stockholders will bear the costs associated with the sale of such shares, including underwriting discounts and commissions. New investors purchasing shares in this transaction include entities managed by Durable Capital Partners LP and Rubicon Founders LLC, among others. Goldman Sachs & Co. LLC acted as the sole book-running manager for the offering.
Privia Health Group announced the pricing of an underwritten secondary offering of 31,319,473 shares of common stock by certain selling stockholders at a price of $22.00 per share. The Company will not receive any of the proceeds from the sale of the shares of its common stock, and the selling stockholders will bear the costs associated with the sale of such shares, including underwriting discounts and commissions. New investors purchasing shares in this transaction include entities managed by Durable Capital Partners LP and Rubicon Founders LLC, among others. Goldman Sachs & Co. LLC acted as the sole book-running manager for the offering.
Privia Health Group announced the commencement of an underwritten secondary offering of 31,319,473 shares of common stock by certain selling stockholders. Goldman Sachs & Co. is acting as the sole book-running manager for the offering.
Privia Health reiterated its full-year 2023 guidance, in which all operating and non-GAAP financial metric guidance initially provided on February 28, 2023 remain unchanged.
